{
    "hands_on_practices": [
        {
            "introduction": "The decision to list a child for lung transplantation is rarely straightforward. This exercise moves beyond single-variable problems to the complex, multi-system evaluations that define modern transplant medicine. By analyzing a patient with several relative contraindications, you will practice the crucial skill of synthesizing diverse clinical data to perform a holistic risk-benefit analysis, a cornerstone of determining transplant candidacy .",
            "id": "5187577",
            "problem": "A $13$-year-old patient with end-stage chronic lung disease is being evaluated for pediatric lung transplantation. The patient has idiopathic severe scoliosis with a Cobb angle of $65^\\circ$, a markedly restrictive chest wall mechanics, and spirometry showing forced vital capacity (FVC) $35\\%$ predicted and forced expiratory volume in $1$ second (FEV$_1$) $38\\%$ predicted. The patient is colonized chronically with multidrug-resistant Pseudomonas aeruginosa; sputum cultures repeatedly demonstrate sensitivity to colistin and ceftolozane/tazobactam, resistance to aminoglycosides, and blood cultures are consistently negative. There is no fever and inflammatory markers are modestly elevated with C-reactive protein $12$ $\\mathrm{mg/L}$. The patient requires supplemental oxygen at $2$ $\\mathrm{L/min}$ at rest, has a $6$-minute walk distance of $220$ $\\mathrm{m}$, and echocardiography estimates pulmonary artery systolic pressure at $45$ $\\mathrm{mmHg}$ (mild pulmonary hypertension). Nutritional status is suboptimal with body mass index (BMI) $15.8$ $\\mathrm{kg/m^2}$. The estimated glomerular filtration rate (eGFR) is $65$ $\\mathrm{mL/min/1.73\\,m^2}$ with serum creatinine $0.9$ $\\mathrm{mg/dL}$, without proteinuria, consistent with mild renal dysfunction. There is no history of malignancy, the patient and family have demonstrated adherence to treatments, and vaccinations are up to date including influenza and Coronavirus Disease $2019$ (COVID-$19$).\n\nUsing foundational principles of transplant candidacy (weighing net survival benefit against perioperative and post-transplant risks), standard distinctions between absolute versus relative contraindications, and core respiratory physiology that links chest wall compliance to alveolar ventilation and postoperative ventilatory support requirements, choose the best statement regarding this patient’s candidacy and the most appropriate risk mitigation plan for proceeding to pediatric lung transplantation.\n\nA. The patient is not a candidate because the combination of severe scoliosis, chronic respiratory tract infection, and mild renal dysfunction constitutes absolute contraindications; transplant listing should be deferred indefinitely.\n\nB. The patient remains a candidate with relative contraindications; risk mitigation should prioritize pretransplant culture-directed eradication protocols and strict infection control, donor size-matching to accommodate a small thoracic cavity, perioperative ventilatory strategies including planned early non-invasive ventilation (NIV) and intensive chest physiotherapy, renal-sparing immunosuppression with interleukin-2 receptor antagonist induction (for example, basiliximab) and delayed or reduced-dose calcineurin inhibitor with close eGFR monitoring, avoidance of nephrotoxins, nutritional optimization, and deferral of elective spinal fusion until after transplant if needed.\n\nC. The patient is a candidate only if spinal fusion is performed before transplantation to increase thoracic volume, broad-spectrum antibiotics are started without culture guidance, and standard-dose tacrolimus is initiated on day $0$; donor size does not need to be matched to the chest cavity.\n\nD. The patient is ineligible because colonization with Pseudomonas aeruginosa is an absolute contraindication; lifelong suppressive antibiotics should be continued and transplant listing withdrawn.\n\nE. The patient should undergo combined lung–kidney transplantation because any renal dysfunction mandates multi-organ transplant; sirolimus-based maintenance immunosuppression should be used early postoperatively to spare renal function.",
            "solution": "This problem requires a comprehensive risk-benefit analysis for a complex pediatric transplant candidate. The patient has a clear indication for transplantation (end-stage lung disease with severe functional limitation) but also several significant comorbidities. The key is to correctly classify these risks and evaluate the proposed management plans.\n\n1.  **Analyze the Contraindications**: The patient's issues—severe scoliosis, chronic colonization with multidrug-resistant *Pseudomonas aeruginosa*, mild renal dysfunction (eGFR $65$ $\\mathrm{mL/min/1.73\\,m^2}$), and poor nutritional status—are all considered **relative contraindications** in modern transplant medicine. They increase perioperative and long-term risk but do not absolutely preclude transplantation if a robust risk-mitigation strategy is in place. No absolute contraindications (e.g., active systemic infection, active malignancy) are present.\n\n2.  **Evaluate the Options Based on this Analysis**:\n\n    *   **A. Incorrect.** It misclassifies the patient's comorbidities as absolute contraindications.\n    *   **C. Incorrect.** This option proposes a dangerous plan: pre-transplant spinal fusion carries prohibitive risk; starting antibiotics without culture guidance is poor practice; initiating standard-dose tacrolimus (a nephrotoxin) would worsen renal function; and ignoring size-matching for a deformed chest is a critical surgical error.\n    *   **D. Incorrect.** Colonization with *P. aeruginosa* is a common challenge, especially in cystic fibrosis patients, and is managed as a relative risk, not an absolute barrier to transplant.\n    *   **E. Incorrect.** A combined lung-kidney transplant is not indicated for mild renal dysfunction (eGFR 65). Furthermore, using sirolimus in the early post-transplant period is generally avoided due to its known adverse effect on bronchial anastomotic (airway) healing.\n    *   **B. Correct.** This option correctly identifies the patient as a high-risk candidate with relative contraindications. It then lays out a perfect, multi-pronged risk-mitigation strategy that addresses every single issue:\n        *   **Infection:** Culture-directed antimicrobial therapy.\n        *   **Scoliosis/Sizing:** Careful donor size-matching and specialized postoperative ventilatory support.\n        *   **Renal dysfunction:** A \"renal-sparing\" immunosuppression protocol using an induction agent (basiliximab) to allow for delayed or reduced-dose calcineurin inhibitors.\n        *   **Other risks:** Nutritional optimization and appropriate deferral of the high-risk spinal fusion surgery until after the patient has recovered from the transplant.\n\nTherefore, option B represents the most appropriate and evidence-based approach to managing this complex patient.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once a patient is listed, the challenge shifts to finding a suitable donor organ, where size matching is a critical determinant of surgical success and early graft function. This problem requires you to apply first principles of respiratory physiology—namely compliance and safe pressure limits—to derive and calculate a quantitative metric for donor-recipient matching. This practice demonstrates how biophysical models inform crucial clinical decisions at the point of organ offer .",
            "id": "5187467",
            "problem": "A pediatric lung transplant team must size-match a donor to a recipient using predicted Total Lung Capacity (pTLC). Assume the following scientifically grounded bases:\n\n- Predicted Total Lung Capacity (pTLC) for children of the same sex in late childhood to adolescence follows a well-tested linear anthropometric relationship based on height, $$\\mathrm{pTLC}(h) = \\alpha h + \\beta,$$ where $h$ is height in $\\mathrm{cm}$ and $\\mathrm{pTLC}$ is in $\\mathrm{L}$. For this cohort, use $$\\alpha = 0.090 \\ \\mathrm{L/cm} \\quad \\text{and} \\quad \\beta = -8.2 \\ \\mathrm{L}.$$\n- Respiratory system compliance for the recipient, $C_{\\mathrm{rs},R}$, is assumed to be approximately constant over the range of interest and is given by $$C_{\\mathrm{rs},R} = 0.17 \\ \\mathrm{L/cmH_2O}.$$\n- The pressure needed to inflate a linear respiratory system model to volume $V$ is $P = V / C$, where $C$ is the compliance. For safe perioperative mechanics, the maximum permissible inflation pressure for the recipient is bounded by a factor $s$ of the recipient’s normal pressure at their own predicted total lung capacity, i.e., $$P_{\\mathrm{safe}} = s \\, P_{\\mathrm{TLC},R}, \\quad \\text{with} \\quad s = 1.10.$$\n\nA $12$-year-old recipient has height $h_R = 138 \\ \\mathrm{cm}$. A potential donor, aged $15$, has height $h_D = 160 \\ \\mathrm{cm}$. Using the definitions and data above:\n\n- Derive, from first principles of compliance and safe pressure, the upper acceptability threshold for the donor-to-recipient size match ratio $M = \\mathrm{pTLC}_D / \\mathrm{pTLC}_R$.\n- Calculate the donor-to-recipient size match ratio $M$ for this pair using the provided anthropometric pTLC relationship.\n\nReport the single final value $M$ as a dimensionless decimal. Round your answer to three significant figures. Do not use a percentage sign. No angles are involved in this problem.",
            "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- The relationship between predicted Total Lung Capacity ($\\mathrm{pTLC}$) and height ($h$) is given by the linear equation $\\mathrm{pTLC}(h) = \\alpha h + \\beta$.\n- The parameters for this equation are $\\alpha = 0.090 \\ \\mathrm{L/cm}$ and $\\beta = -8.2 \\ \\mathrm{L}$.\n- The recipient's respiratory system compliance is $C_{\\mathrm{rs},R} = 0.17 \\ \\mathrm{L/cmH_2O}$.\n- The pressure ($P$) required to inflate a linear respiratory system model to a volume ($V$) is $P = V / C$, where $C$ is the compliance.\n- The maximum permissible inflation pressure ($P_{\\mathrm{safe}}$) is a factor $s$ of the recipient's normal pressure at their own predicted total lung capacity ($P_{\\mathrm{TLC},R}$), given by $P_{\\mathrm{safe}} = s \\, P_{\\mathrm{TLC},R}$.\n- The safety factor is $s = 1.10$.\n- The recipient's height is $h_R = 138 \\ \\mathrm{cm}$.\n- The donor's height is $h_D = 160 \\ \\mathrm{cm}$.\n- The donor-to-recipient size match ratio is defined as $M = \\mathrm{pTLC}_D / \\mathrm{pTLC}_R$.\n- The tasks are to derive the upper acceptability threshold for $M$ and to calculate the value of $M$ for the specified donor-recipient pair.\n- The final answer is to be the calculated value of $M$, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is grounded in fundamental principles of respiratory physiology. The linear model for pTLC is a standard simplification for specific demographic cohorts. The relationship $P = V/C$ is a direct definition of static compliance. The concept of a safe pressure limit is a cornerstone of mechanical ventilation and perioperative care. The provided numerical values for $\\alpha$, $\\beta$, and $C_{\\mathrm{rs},R}$ are physiologically plausible for the pediatric/adolescent population described.\n- **Well-Posed**: The problem provides all necessary definitions, constants, and variables to perform the two requested tasks. A unique solution exists for both the derivation and the calculation. Although two tasks are requested, the final reporting instruction is unambiguous, clarifying that only the calculated value of $M$ for the specific pair should be the final answer.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language.\n- **Consistency and Feasibility**: The units are consistent ($\\mathrm{L}$, $\\mathrm{cm}$, $\\mathrm{L/cm}$, $\\mathrm{L/cmH_2O}$). The model is internally consistent. A preliminary check of the pTLC values derived from the heights yields positive, realistic lung volumes. For $h_R = 138 \\ \\mathrm{cm}$, $\\mathrm{pTLC}_R = (0.090)(138) - 8.2 = 4.22 \\ \\mathrm{L}$. For $h_D = 160 \\ \\mathrm{cm}$, $\\mathrm{pTLC}_D = (0.090)(160) - 8.2 = 6.2 \\ \\mathrm{L}$. These are reasonable values.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, and internally consistent. It is deemed **valid**. A full solution will be provided.\n\n### Solution\nThe problem requires two sequential parts: first, a derivation of the upper threshold for the size-match ratio $M$, and second, the calculation of $M$ for the given donor and recipient.\n\n**Part 1: Derivation of the Upper Acceptability Threshold for $M$**\n\nThe derivation begins from the principle of safe inflation pressure within the recipient's chest.\nThe pressure required to inflate the recipient's native lungs to their own predicted total lung capacity, $\\mathrm{pTLC}_R$, is given by the compliance relationship:\n$$P_{\\mathrm{TLC},R} = \\frac{\\mathrm{pTLC}_R}{C_{\\mathrm{rs},R}}$$\nThe maximum safe inflation pressure, $P_{\\mathrm{safe}}$, is defined as a multiple of this pressure:\n$$P_{\\mathrm{safe}} = s \\cdot P_{\\mathrm{TLC},R} = s \\frac{\\mathrm{pTLC}_R}{C_{\\mathrm{rs},R}}$$\nAfter transplantation, the donor lung is housed within the recipient's thoracic cavity. The properties of the recipient's chest wall and diaphragm dictate the pressure-volume relationship, which is characterized by the recipient's compliance, $C_{\\mathrm{rs},R}$. Therefore, the maximum volume, $V_{\\mathrm{max}}$, that can be safely accommodated in the recipient's chest is the volume that would generate the pressure $P_{\\mathrm{safe}}$:\n$$P_{\\mathrm{safe}} = \\frac{V_{\\mathrm{max}}}{C_{\\mathrm{rs},R}}$$\nSolving for $V_{\\mathrm{max}}$ yields:\n$$V_{\\mathrm{max}} = P_{\\mathrm{safe}} \\cdot C_{\\mathrm{rs},R}$$\nSubstituting the expression for $P_{\\mathrm{safe}}$ into this equation:\n$$V_{\\mathrm{max}} = \\left( s \\frac{\\mathrm{pTLC}_R}{C_{\\mathrm{rs},R}} \\right) \\cdot C_{\\mathrm{rs},R}$$\nThe recipient's compliance, $C_{\\mathrm{rs},R}$, cancels out, showing that the maximum acceptable volume is independent of the specific compliance value, a key insight from the model:\n$$V_{\\mathrm{max}} = s \\cdot \\mathrm{pTLC}_R$$\nFor a successful transplant under these safety criteria, the donor's predicted total lung capacity, $\\mathrm{pTLC}_D$, must not exceed this maximum volume:\n$$\\mathrm{pTLC}_D \\le V_{\\mathrm{max}}$$\n$$\\mathrm{pTLC}_D \\le s \\cdot \\mathrm{pTLC}_R$$\nThe donor-to-recipient size match ratio is $M = \\mathrm{pTLC}_D / \\mathrm{pTLC}_R$. To find the upper threshold for $M$, we divide the inequality by $\\mathrm{pTLC}_R$ (a strictly positive quantity):\n$$\\frac{\\mathrm{pTLC}_D}{\\mathrm{pTLC}_R} \\le s$$\n$$M \\le s$$\nThus, the upper acceptability threshold for the size-match ratio $M$ is the safety factor $s$ itself. Given $s = 1.10$, any match with $M > 1.10$ would be considered oversized.\n\n**Part 2: Calculation of the Specific Size Match Ratio $M$**\n\nThe problem asks for the calculation of $M$ for the specific donor-recipient pair. First, we calculate the predicted total lung capacity for the recipient ($\\mathrm{pTLC}_R$) and the donor ($\\mathrm{pTLC}_D$) using the given anthropometric formula, $\\mathrm{pTLC}(h) = \\alpha h + \\beta$.\n\nFor the recipient with height $h_R = 138 \\ \\mathrm{cm}$:\n$$\\mathrm{pTLC}_R = (0.090 \\ \\mathrm{L/cm})(138 \\ \\mathrm{cm}) + (-8.2 \\ \\mathrm{L})$$\n$$\\mathrm{pTLC}_R = 12.42 \\ \\mathrm{L} - 8.2 \\ \\mathrm{L} = 4.22 \\ \\mathrm{L}$$\n\nFor the donor with height $h_D = 160 \\ \\mathrm{cm}$:\n$$\\mathrm{pTLC}_D = (0.090 \\ \\mathrm{L/cm})(160 \\ \\mathrm{cm}) + (-8.2 \\ \\mathrm{L})$$\n$$\\mathrm{pTLC}_D = 14.4 \\ \\mathrm{L} - 8.2 \\ \\mathrm{L} = 6.2 \\ \\mathrm{L}$$\n\nNow, we calculate the donor-to-recipient size match ratio, $M$:\n$$M = \\frac{\\mathrm{pTLC}_D}{\\mathrm{pTLC}_R} = \\frac{6.2 \\ \\mathrm{L}}{4.22 \\ \\mathrm{L}}$$\n$$M \\approx 1.4691943...$$\nThe problem requires the answer to be rounded to three significant figures.\n$$M \\approx 1.47$$\nThis value is the specific size match ratio for the given pair.",
            "answer": "$$\\boxed{1.47}$$"
        },
        {
            "introduction": "Successful surgery marks the beginning of lifelong, dynamic medical management, with immunosuppression at its core. This exercise presents a common and critical post-transplant scenario: a significant drug-drug interaction affecting a calcineurin inhibitor. You will use fundamental pharmacokinetic principles to calculate a necessary dose adjustment, a practical skill essential for preventing graft rejection while avoiding drug toxicity .",
            "id": "5187516",
            "problem": "A $9$-year-old child, $4$ weeks after pediatric bilateral lung transplantation, is maintained on immediate-release tacrolimus administered every $12$ hours at a total daily dose of $3.6 \\ \\text{mg}$. Before any interacting medications, the tacrolimus trough concentration at steady state was $9.5 \\ \\text{ng/mL}$. The target trough range for this phase of post-transplant care is $8$ to $12 \\ \\text{ng/mL}$. The child is started on posaconazole, a strong inhibitor of Cytochrome P450 $3\\text{A}$ (CYP3A), for treatment of invasive fungal infection. After $5$ days on posaconazole, with no change in tacrolimus dosing, the measured tacrolimus trough concentration at steady state is $26 \\ \\text{ng/mL}$. Assume tacrolimus exhibits linear, first-order pharmacokinetics, and that bioavailability and the elimination rate constant are unchanged aside from the effect of the inhibitor, which is now fully expressed. Using fundamental pharmacokinetic reasoning about steady-state concentration proportionality, calculate the new total daily tacrolimus dose (in mg) needed to achieve the midpoint of the target trough range. Round your answer to three significant figures and express the dose in mg.",
            "solution": "The problem requires the calculation of a new total daily dose of tacrolimus for a pediatric patient after the introduction of posaconazole, an enzyme inhibitor. The solution relies on the principles of linear, first-order pharmacokinetics.\n\nThe fundamental principle is that for a drug exhibiting linear pharmacokinetics, at steady state, any given concentration measurement (such as the trough concentration, $C_{ss,trough}$) is directly proportional to the rate of drug administration. For oral medications, this rate is a function of the total daily dose, $TDD$. This relationship can be expressed as:\n$$ C_{ss,trough} = K \\times TDD $$\nwhere $K$ is a constant of proportionality that encapsulates the patient's unique pharmacokinetic parameters, including bioavailability ($F$), volume of distribution ($V_d$), and clearance ($CL$).\n\nThe problem describes a scenario where the patient is initially on a total daily dose of $3.6 \\ \\text{mg}$ of tacrolimus, resulting in a trough concentration of $9.5 \\ \\text{ng/mL}$. The patient is then started on posaconazole, a strong inhibitor of the Cytochrome P450 $3\\text{A}$ (CYP3A) enzyme system, which is the primary route of metabolism for tacrolimus. This inhibition reduces the drug's clearance ($CL$), leading to a higher plasma concentration for the same dose.\n\nAfter $5$ days on posaconazole, a new steady state is achieved. With the same total daily dose, $TDD_1 = 3.6 \\ \\text{mg}$, the measured trough concentration is now $C_{ss,trough,1} = 26 \\ \\text{ng/mL}$. This new state is governed by a new proportionality constant, $K_{inhibited}$, which reflects the reduced clearance of tacrolimus. The relationship is:\n$$ C_{ss,trough,1} = K_{inhibited} \\times TDD_1 $$\n\nThe clinical goal is to adjust the dose to achieve a new target trough concentration, $C_{ss,trough,target}$, which is the midpoint of the specified target range of $8 \\ \\text{ng/mL}$ to $12 \\ \\text{ng/mL}$.\n$$ C_{ss,trough,target} = \\frac{8 + 12}{2} \\ \\text{ng/mL} = 10 \\ \\text{ng/mL} $$\nWe need to find the new total daily dose, $TDD_{new}$, that will achieve this target concentration in the presence of the inhibitor. The relationship for this target state is:\n$$ C_{ss,trough,target} = K_{inhibited} \\times TDD_{new} $$\n\nBecause both the measured high-concentration state and the desired target state occur in the presence of the inhibitor, the proportionality constant $K_{inhibited}$ is the same for both. Therefore, we can set up a ratio:\n$$ \\frac{C_{ss,trough,1}}{TDD_1} = K_{inhibited} = \\frac{C_{ss,trough,target}}{TDD_{new}} $$\nThis allows us to solve for the unknown new dose, $TDD_{new}$:\n$$ TDD_{new} = TDD_1 \\times \\frac{C_{ss,trough,target}}{C_{ss,trough,1}} $$\n\nWe now substitute the known values into this equation:\n$TDD_1 = 3.6 \\ \\text{mg}$\n$C_{ss,trough,1} = 26 \\ \\text{ng/mL}$\n$C_{ss,trough,target} = 10 \\ \\text{ng/mL}$\n\n$$ TDD_{new} = 3.6 \\ \\text{mg} \\times \\frac{10 \\ \\text{ng/mL}}{26 \\ \\text{ng/mL}} $$\nThe units of concentration ($\\text{ng/mL}$) cancel, leaving the dose in units of $\\text{mg}$.\n$$ TDD_{new} = 3.6 \\times \\frac{10}{26} \\ \\text{mg} = \\frac{36}{26} \\ \\text{mg} = \\frac{18}{13} \\ \\text{mg} $$\n\nFinally, we calculate the numerical value and round to three significant figures as requested by the problem statement.\n$$ TDD_{new} \\approx 1.38461538\\dots \\ \\text{mg} $$\nRounding to three significant figures, the new total daily dose is:\n$$ TDD_{new} \\approx 1.38 \\ \\text{mg} $$\nThe pre-interaction data ($C_{ss,trough} = 9.5 \\ \\text{ng/mL}$) is consistent with the scenario and serves to contextualize the magnitude of the drug interaction, but it is not required for the dose adjustment calculation itself, which relies only on the post-interaction concentration and the target concentration.",
            "answer": "$$\\boxed{1.38}$$"
        }
    ]
}